GSK Lamictal Packaging Altered In Lieu Of FDA-Suggested Name Change
Executive Summary
GlaxoSmithKline is altering packaging for the anti-epileptic Lamictal to help reduce medical errors as a compromise in lieu of FDA's suggestion to change the brand name.